IMJUDO
Active substance: tremelimumab
INJECTION, SOLUTION · TREMELIMUMAB 300 mg/15mL
United StatesActive
Marketing holder: AstraZeneca Pharmaceuticals LP
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- TREMELIMUMAB · 300 mg/15mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 2 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a12090-7c03-785d-afec-a14ad0809cf7,01a12090-7c18-70c2-9fc7-e2a165adddd8;count=2 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 0310-4535
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- INTRAVENOUS
Sources
- product · openFDA NDC · 0310-4535 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 0310-4535 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 0310-4535 · Verified 2026-10-09 · open in source